Table 1

Baseline patient demographics and characteristics

CharacteristicAll patientsICB-naïveICB-experienced
UBCMELNSCLCUBC
N=221N=41N=18N=40N=12
Sex, n (%)
 Male144 (65.2)32 (78.0)12 (66.7)31 (77.5)10 (83.3)
 Female77 (34.8)9 (22.0)6 (33.3)9 (22.5)2 (16.7)
Age (years), median (range)62 (18–86)67.0 (49–83)60 (36–83)63 (29–80)66 (59–86)
ECOG score at baseline, n (%)
 0101 (45.7)20 (48.8)10 (55.6)17 (42.5)7 (58.3)
 1116 (52.5)21 (51.2)8 (44.4)23 (57.5)5 (41.7)
 22 (0.9)0000
Median LDH at baseline (range, U/L)224 (93, 8147)207 (113, 8147)284 (134, 3515)246 (155, 754)196 (118, 391)
Patients with liver metastases, n (%)87 (39.4)14 (34.1)8 (44.4)7 (17.5)4 (33.3)
Patients’ PD-L1 IHC status from available tumor tissue3414239
IC
 029 (85.3)6 (42.9)10 (43.5)2 (22.2)
 15 (14.7)3 (21.4)7 (30.4)4 (44.4)
 202 (14.3)3 (13.0)1 (11.1)
 3003 (13.0)0
 NA03 (21.4)02 (22.2)
TC
 029 (85.3)7 (50.0)12 (52.2)5 (55.6)
 13 (8.8)2 (14.3)3 (13.0)1 (11.1)
 22 (5.9)2 (14.3)6 (26.1)1 (11.1)
 3002 (8.7)0
 NA03 (21.4)02 (22.2)
Prior anti-cancer therapy lines median no (range)3 (0–10)2 (1– 6)2 (1–7)2 (1–9)2 (1–5)
Duration of prior immunotherapy, median and range (days)98 (35–807)126 (14–854)102 (48–634)
Time from prior immunotherapy to study treatment, median and range (days)182.5 (82–911)205 (89–902)168 (97–698)
ORR to prior immunotherapy, n (%)06 (15.0)*4 (33.3)†
Prior surgery, n (%)194 (87.8)38 (95.0)16 (88.9)24 (60.0)12 (100)
Prior radiotherapy96 (43.4)13 (32.5)9 (50.0)22 (55.0)3 (25.0)
Tumor type, n (%)
 Urothelial bladder cancer67 (30.3)41 (100)12 (100)
 Non-small cell lung cancer41 (18.6)40 (100)
 Gastric cancer20 (9.0)
 Melanoma18 (8.1)18 (100)
 Ovarian cancer17 (7.7)
 Soft tissue sarcoma17 (7.7)
 Triple-negative breast cancer17 (7.7)
 Other13 (5.9)
 Colorectal11 (5.0)
No of cycles of study treatment
 Atezolizumab, median (range)4 (1–68)4 (1–52)5 (1–21)4 (1–29)2 (1–44)
 Emactuzumab, median (range)3 (1–68)3 (1–52)4 (1–18)3.5 (1–19)2 (1–7)
  • *Two patients were not evaluable for prior response.

  • †One patient was not evaluable for prior response.

  • ECOG, Eastern Cooperative Oncology Group; IC, immune cells; ICB, immune checkpoint blocker; IHC, immunohistochemistry; LDH, lactate dehydrogenase; MEL, melanoma; NA, not applicable; NSCLC, non-small cell lung cancer; ORR, objective response rate; TC, tumor cells; UBC, urothelial bladder cancer.